ArticleObesity surgery2026
Metabolic Outcomes and Recurrent Weight Gain 10 Years After Roux-en-Y Gastric Bypass, a Longitudinal Cohort Study.
Article in Obesity surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionLong-term weight loss and improvement in associated medical problems are seen after metabolic bariatric surgery (MBS) as Roux-en-Y gastric bypass (RYGB). Few studies have focused on recurrent weight gain (RWG) after RYGB.
methodsPatients operated with RYGB from 2004 to 2008 were invited to 10-year follow-up consultations. The primary outcome was weight development in terms of total weight loss and RWG. Significant RWG was defined as gaining > 30% of initial weight loss two years postoperatively. Secondary outcomes included associated medical problems.
resultsAmong a total of 582 patients operated, 311/544 (56%) patients attended 10-year follow-up. Mean age at 10 years was 52.8 (9.2) years, with 76.5% females. Body mass index (BMI), weight and total weight loss at 10-year follow-up were 35.6 (6.8) kg/m2, 103.7 (24.1) kg and 23.4 (12.3) %, respectively. RWG at 10-year follow-up was 26.0 (48.8) %, with 45.6% of the patients experiencing RWG > 30%. For patients with and without RWG > 30%, the relapse and remission rates of diabetes type 2 and hypertension were comparable. Relapse rates of dyslipidemia were higher in patients with RWG > 30%.
conclusionWe found a high prevalence of significant RWG 10 years after RYGB. Except for dyslipidemia, the metabolic benefits of RYGB persisted despite RWG.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.